Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at

Articles by Eric Palmer

Valeant's Bausch + Lomb recalls more than 1M bottles of eye med

Valeant's Bausch + Lomb has voluntarily initiated a massive recall of an eye dilation med after learning that more than 1 million bottles may have been shipped with the wrong medication insert.

Sanofi commits to developing Zika vax while other big players will evaluate

Sanofi says it intends to apply its decades of vaccine development work and manufacturing expertise in dengue fever to try to create a vaccine for Zika virus, the mosquito-borne disease that the World Health Organization this week called a global health emergency.

Ipca's small-scale API producer in U.K. expanding

India's Ipca Laboratories is facing FDA regulatory actions at plants in India, but the drugmaker's small-scale API and CRO operation in the U.K. intends to again increase capacity, this time by about 30%.

Pakistani man charged with bringing counterfeit drugs into U.S.

Ever wonder where the websites selling unapproved and sometimes counterfeit drugs get those products? According to the Department of Justice, many of them came from a Pakistani man and his company, JNS Impex.

Sanofi says job cuts in France should not involve plant closures

Sanofi is looking to trim 600 jobs in France as part of new CEO Olivier Brandicourt's plan to squeeze €1.5 billion in annual costs. The drugmaker says it does not plan on closing any plants in France as part of the process, but that does not mean that its production network in the home country will escape unscathed. Brandicourt has also said he will "reshape" the manufacturing network as part of his overall reorganization of the company.

Piramal expanding, beefing up ADC capabilities of U.S. operation

Piramal Enterprises, with a big dose of incentives, snapped up Coldstream Laboratories last year from the University of Kentucky to get its expertise in sterile injectable meds. Now it has plans on investing another sizable chunk to expand the CDMO.

Troubled Sun Pharma manages U.S. launch of copy of blockbuster Gleevec

Sun Pharmaceutical, which has had its U.S. sales gut-kicked as its deal with FDA concerns at some of its manufacturing plants, has launched in the U.S. its copy of Novartis' blockbuster blood cancer drug Gleevec. With its first-to-file approval, the Sun generic will have the market to itself for 6 months.

FDA finds faults with one of two Aurobindo plants it inspects

India's Aurobindo Pharma, in the midst of expanding its manufacturing targeted at the U.S., has gotten a production unit signed off on by the FDA. A second one, however, came up short of the finish line.

FDA hands Wockhardt and Ipca more disappointing news

It has been another tough week for some of India's troubled drugmakers. Wockhardt, which has two plants banned by the FDA, saw its hopes stymied for getting export approval for a different facility that it had hoped could help it recoup some of its lost U.S. revenues. And India's Ipca Laboratories, which has three plants on the import alert list, said Monday it has now gotten a warning letter for the facilities.

Teva U.K. plant cuts 80 jobs as drugmaker looks for higher skilled workers

Teva Pharmaceuticals' efforts to cut costs by making its manufacturing more efficient have landed at a plant in the U.K. where the generics leader will cut dozens of jobs but add some new positions with more specialized skills.